Pulmonary Abnormalities in Liver Disease: Relevance to Transplantation and Outcome
Corresponding Author
Sarah Raevens
Department of Gastroenterology and Hepatology, Ghent University-Ghent University Hospital, Ghent, Belgium
ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:
Sarah Raevens, M.D., Ph.D.
Department of Gastroenterology and Hepatology, Ghent University Hospital
Building K12 First Floor IE
Corneel Heymanslaan 10
9000 Ghent, Belgium
E-mail: [email protected]
Tel.: +32 9 332 53 01
or
Michael B. Fallon, M.D.
Department of Internal Medicine, University of Arizona College of Medicine
550 East Van Buren Street
Phoenix, AZ 85004
E-mail: [email protected]
Tel.: +1-602-827-2078
Search for more papers by this authorMaxine Boret
Department of Gastroenterology and Hepatology, Ghent University-Ghent University Hospital, Ghent, Belgium
Search for more papers by this authorMichel De Pauw
Department of Cardiology, Ghent University-Ghent University Hospital, Ghent, Belgium
Search for more papers by this authorCorresponding Author
Michael B. Fallon
Department of Internal Medicine, University of Arizona College of Medicine, Phoenix, AZ
These authors share senior authorship.ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:
Sarah Raevens, M.D., Ph.D.
Department of Gastroenterology and Hepatology, Ghent University Hospital
Building K12 First Floor IE
Corneel Heymanslaan 10
9000 Ghent, Belgium
E-mail: [email protected]
Tel.: +32 9 332 53 01
or
Michael B. Fallon, M.D.
Department of Internal Medicine, University of Arizona College of Medicine
550 East Van Buren Street
Phoenix, AZ 85004
E-mail: [email protected]
Tel.: +1-602-827-2078
Search for more papers by this authorHans Van Vlierberghe
Department of Gastroenterology and Hepatology, Ghent University-Ghent University Hospital, Ghent, Belgium
These authors share senior authorship.Search for more papers by this authorCorresponding Author
Sarah Raevens
Department of Gastroenterology and Hepatology, Ghent University-Ghent University Hospital, Ghent, Belgium
ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:
Sarah Raevens, M.D., Ph.D.
Department of Gastroenterology and Hepatology, Ghent University Hospital
Building K12 First Floor IE
Corneel Heymanslaan 10
9000 Ghent, Belgium
E-mail: [email protected]
Tel.: +32 9 332 53 01
or
Michael B. Fallon, M.D.
Department of Internal Medicine, University of Arizona College of Medicine
550 East Van Buren Street
Phoenix, AZ 85004
E-mail: [email protected]
Tel.: +1-602-827-2078
Search for more papers by this authorMaxine Boret
Department of Gastroenterology and Hepatology, Ghent University-Ghent University Hospital, Ghent, Belgium
Search for more papers by this authorMichel De Pauw
Department of Cardiology, Ghent University-Ghent University Hospital, Ghent, Belgium
Search for more papers by this authorCorresponding Author
Michael B. Fallon
Department of Internal Medicine, University of Arizona College of Medicine, Phoenix, AZ
These authors share senior authorship.ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:
Sarah Raevens, M.D., Ph.D.
Department of Gastroenterology and Hepatology, Ghent University Hospital
Building K12 First Floor IE
Corneel Heymanslaan 10
9000 Ghent, Belgium
E-mail: [email protected]
Tel.: +32 9 332 53 01
or
Michael B. Fallon, M.D.
Department of Internal Medicine, University of Arizona College of Medicine
550 East Van Buren Street
Phoenix, AZ 85004
E-mail: [email protected]
Tel.: +1-602-827-2078
Search for more papers by this authorHans Van Vlierberghe
Department of Gastroenterology and Hepatology, Ghent University-Ghent University Hospital, Ghent, Belgium
These authors share senior authorship.Search for more papers by this authorAbstract
Pulmonary disease in liver cirrhosis and portal hypertension (PH) constitutes a challenging clinical scenario and may have important implications with regard to prognosis, liver transplantation (LT) candidacy, and post-LT outcome. Pre-LT evaluation should include adequate screening for pulmonary diseases that may occur concomitantly with liver disease as well as for those that may arise as a complication of end-stage liver disease and PH, given that either may jeopardize safe LT and successful outcome. It is key to discriminate those patients who would benefit from LT, especially pulmonary disorders that have been reported to resolve post-LT and are considered “pulmonary indications” for transplant, from those who are at increased mortality risk and in whom LT is contraindicated. In conclusion, in this article, we review the impact of several pulmonary disorders, including cystic fibrosis, alpha 1-antitrypsin deficiency, hereditary hemorrhagic telangiectasia, sarcoidosis, coronavirus disease 2019, asthma, chronic obstructive pulmonary disease, pulmonary nodules, interstitial lung disease, hepatic hydrothorax, hepatopulmonary syndrome, and portopulmonary hypertension, on post-LT survival, as well as the reciprocal impact of LT on the evolution of lung function.
References
- 1 Organ Procurement and Transplantation Network, Resources: Liver and Intestine. Eurotransplant Manual Professionals, Chapter 5: ET Liver Allocation System (ELAS). Version 2021. In: Guidance to Liver Transplant Programs and the National Liver Review Board for: Adult MELD Exception Review. https://optn.transplant.hrsa.gov/resources/by-organ/liver-intestine/, https://optn.transplant.hrsa.gov/media/2847/liver_guidance_adult_meld_201706.pdf. Accessed January 2021.
- 2 Eurotransplant Liver Allocation System (ELAS). Eurotransplant Manual©—version 5.15. 2019. www.eurotransplant.org/wp-content/uploads/2020/01/H5-ELAS-MELD.pdf. Accessed January 2021.
- 3Davison S. Assessment of liver disease in cystic fibrosis. Paediatr Respir Rev 2018; 27: 24-27.
- 4Feigelson J, Anagnostopoulos C, Poquet M, Pecau Y, Munck A, Navarro J. Liver cirrhosis in cystic fibrosis—therapeutic implications and long term follow up. Arch Dis Child 1993; 68: 653-657.
- 5Melzi ML, Kelly DA, Colombo C, Jara P, Manzanares J, Colledan M, et al. Liver transplant in cystic fibrosis: a poll among European centers. A study from the European Liver Transplant Registry. Transpl Int 2006; 19: 726-731.
- 6Arnon R, Annunziato RA, Miloh T, Padilla M, Sogawa H, Batemarco L, et al. Liver and combined lung and liver transplantation for cystic fibrosis: analysis of the UNOS database. Pediatr Transplant 2011; 15: 254-264.
- 7Desai CS, Gruessner A, Habib S, Gruessner R, Khan KM. Survival of cystic fibrosis patients undergoing liver and liver-lung transplantations. Transplant Proc 2013; 45: 290-292.
- 8Hadzic N. Therapeutic options in alpha-1 antitrypsin deficiency: liver transplantation. Methods Mol Biol 2017; 1639: 263-265.
- 9Kemmer N, Kaiser T, Zacharias V, Neff GW. Alpha-1-antitrypsin deficiency: outcomes after liver transplantation. Transplant Proc 2008; 40: 1492-1494.
- 10Vennarecci G, Gunson BK, Ismail T, Hubscher SG, Kelly DA, McMaster P, et al. Transplantation for end stage liver disease related to alpha 1 antitrypsin. Transplantation 1996; 61: 1488-1495.
- 11Jain AB, Patil V, Sheikh B, Apostolakos M, Ryan C, Kashyap R, et al. Effect of liver transplant on pulmonary functions in adult patients with alpha 1 antitrypsin deficiency: 7 cases. Exp Clin Transplant 2010; 8: 4-8.
- 12Carey EJ, Iyer VN, Nelson DR, Nguyen JH, Krowka MJ. Outcomes for recipients of liver transplantation for alpha-1-antitrypsin deficiency-related cirrhosis. Liver Transpl 2013; 19: 1370-1376.
- 13Garcia-Tsao G. Liver involvement in hereditary hemorrhagic telangiectasia (HHT). J Hepatol 2007; 46: 499-507.
- 14Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 2012; 307: 948-955.
- 15Lerut J, Orlando G, Adam R, Sabba C, Pfitzmann R, Klempnauer J, et al. Liver transplantation for hereditary hemorrhagic telangiectasia: report of the European Liver Transplant Registry. Ann Surg 2006; 244: 854-862.
- 16Dupuis-Girod S, Chesnais AL, Ginon I, Dumortier J, Saurin JC, Finet G, et al. Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study. Liver Transpl 2010; 16: 340-347.
- 17Iyer VN, Saberi B, Heimbach JK, Larson JJ, Raghavaiah S, Ditah I, et al. Liver transplantation trends and outcomes for hereditary hemorrhagic telangiectasia in the United States. Transplantation 2019; 103: 1418-1424.
- 18Dumortier J, Dupuis-Girod S, Valette PJ, Valent A, Guillaud O, Saurin JC, et al. Recurrence of hereditary hemorrhagic telangiectasia after liver transplantation: clinical implications and physiopathological insights. Hepatology 2019; 69: 2232-2240.
- 19Tadros M, Forouhar F, Wu GY. Hepatic sarcoidosis. J Clin Transl Hepatol 2013; 1: 87-93.
- 20Bilal M, Satapathy SK, Ismail MK, Vanatta JM. Long-term outcomes of liver transplantation for hepatic sarcoidosis: a single center experience. J Clin Exp Hepatol 2016; 6: 94-99.
- 21Vanatta JM, Modanlou KA, Dean AG, Nezakatgoo N, Campos L, Nair S, et al. Outcomes of orthotopic liver transplantation for hepatic sarcoidosis: an analysis of the United Network for Organ Sharing/Organ Procurement and Transplantation Network data files for a comparative study with cholestatic liver diseases. Liver Transpl 2011; 17: 1027-1034.
- 22Thuluvath AJ, Savva Y, Chen PH. Poor graft and patient survival after liver transplantation in sarcoidosis. J Clin Gastroenterol 2020; 54: 884-890.
- 23Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and liver. J Hepatol 2020; 73: 1231-1240.
- 24Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020; 5: 428-430.
- 25Iavarone M, D’Ambrosio R, Soria A, Triolo M, Pugliese N, Del PP, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol 2020; 73: 1063-1071.
- 26Kovalic AJ, Satapathy SK, Thuluvath PJ. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatol Int 2020; 14: 612-620.
- 27Di Maira T, Berenguer M. COVID-19 and liver transplantation. Nat Rev Gastroenterol Hepatol 2020; 17: 526-528.
- 28Kumar D, Tellier R, Draker R, Levy G, Humar A. Severe Acute Respiratory Syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening. Am J Transplant 2003; 3: 977-981.
- 29Becchetti C, Zambelli MF, Pasulo L, Donato MF, Invernizzi F, Detry O, et al. COVID-19 in an international European liver transplant recipient cohort. Gut 2020; 69: 1832-1840.
- 30Webb GJ, Marjot T, Cook JA, Aloman C, Armstrong MJ, Brenner EJ, et al. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol Hepatol 2020; 5: 1008-1016.
- 31Bhoori S, Rossi RE, Citterio D, Mazzaferro V. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. Lancet Gastroenterol Hepatol 2020; 5: 532-533.
- 32Belli LS, Duvoux C, Karam V, Adam R, Cuervas-Mons V, Pasulo L, et al. COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. Lancet Gastroenterol Hepatol 2020; 5: 724-725.
- 33Kia L, Cuttica MJ, Yang A, Donnan EN, Whitsett M, Singhvi A, et al. The utility of pulmonary function testing in predicting outcomes following liver transplantation. Liver Transpl 2016; 22: 805-811.
- 34Rybak D, Fallon MB, Krowka MJ, Brown RS, Jr., Reinen J, Stadheim L, et al. Risk factors and impact of chronic obstructive pulmonary disease in candidates for liver transplantation. Liver Transpl 2008; 14: 1357-1365.
- 35de Miguel-Diez J, Jimenez-Garcia R, Hernandez-Barrera V, de Miguel-Yanes JM, Mendez-Bailon M, Lopez-de-Andres A. National trends in kidney, heart and liver transplants among patients with and without chronic obstructive pulmonary disease in Spain (2001-2015). Int J Chron Obstruct Pulmon Dis 2019; 14: 2235-2243.
- 36Concejero AM, Yong CC, Chen CL, Lu HI, Wang CC, Wang SH, et al. Solitary pulmonary nodule in the liver transplant candidate: importance of diagnosis and treatment. Liver Transpl 2010; 16: 760-766.
- 37DuBrock HM, Krowka MJ, Krok K, Forde K, Mottram C, Scanlon P, et al. Prevalence and impact of restrictive lung disease in liver transplant candidates. Liver Transpl 2020; 26: 989-999.
- 38Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007; 176: 277-284.
- 39Kapuria D, Ben-Yakov G, Ortolano R, Cho MH, Kalchiem-Dekel O, Takyar V, et al. The spectrum of hepatic involvement in patients with telomere disease. Hepatology 2019; 69: 2579-2585.
- 40Gorgy AI, Jonassaint NL, Stanley SE, Koteish A, DeZern AE, Walter JE, et al. Hepatopulmonary syndrome is a frequent cause of dyspnea in the short telomere disorders. Chest 2015; 148: 1019-1026.
- 41Badillo R, Rockey DC. Hepatic hydrothorax: clinical features, management, and outcomes in 77 patients and review of the literature. Medicine 2014; 93: 135-142.
- 42Xiol X, Tremosa G, Castellote J, Gornals J, Lama C, Lopez C, et al. Liver transplantation in patients with hepatic hydrothorax. Transpl Int 2005; 18: 672-675.
- 43Serste T, Moreno C, Francoz C, Razek WA, Paugham C, Belghitti J, et al. The impact of preoperative hepatic hydrothorax on the outcome of adult liver transplantation. Eur J Gastroenterol Hepatol 2010; 22: 207-212.
- 44Fallon MB, Krowka MJ, Brown RS, Trotter JF, Zacks S, Roberts KE, et al. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology 2008; 135: 1168-1175.
- 45Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology 2005; 41: 1122-1129.
- 46Arguedas MR, Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 2003; 37: 192-197.
- 47Goldberg DS, Krok K, Batra S, Trotter JF, Kawut SM, Fallon MB. Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database. Gastroenterology 2014; 146: 1256-1265.
- 48Iyer VN, Swanson KL, Cartin-Ceba R, Dierkhising RA, Rosen CB, Heimbach JK, et al. Hepatopulmonary syndrome: favorable outcomes in the MELD exception era. Hepatology 2013; 57: 2427-2435.
- 49Gupta S, Castel H, Rao RV, Picard M, Lilly L, Faughnan ME, et al. Improved survival after liver transplantation in patients with hepatopulmonary syndrome. Am J Transplant 2010; 10: 354-363.
- 50Aragon Pinto CN, Iyer VN, Albitar HAH, Gallo de Moraes A. Outcomes after liver transplantation in patients with hepatopulmonary syndrome in the pre- and post-MELD eras: a systematic review [Abstract]. Am J Respir Crit Care Med 2020; 201:A3778.
- 51Raevens S, Rogiers X, Geerts A, Verhelst X, Samuel U, van Rosmalen M, et al. Outcome of liver transplantation for hepatopulmonary syndrome: a Eurotransplant experience. Eur Respir J 2019; 53:1801096.
- 52Nayyar D, Man HS, Granton J, Lilly LB, Gupta S. Proposed management algorithm for severe hypoxemia after liver transplantation in the hepatopulmonary syndrome. Am J Transplant 2015; 15: 903-913.
- 53Braun HJ, Pulcrano ME, Weber DJ, Padilla BE, Ascher NL. The utility of ECMO after liver transplantation: experience at a high-volume transplant center and review of the literature. Transplantation 2019; 103: 1568-1573.
- 54Levesque E, Salloum C, Feray C, Azoulay D. The utility of ECMO, not just after but also during liver transplantation. Transplantation 2019; 103: e319-e320.
- 55Aragon Pinto CN, Gallo de Moraes A, Albitar HAH, Almodallal YA, DuBrock HM, Cajigas HR, et al. Short and long term oxygenation outcomes after liver transplantation for hepatopulmonary syndrome. Am J Respir Crit Care Med 2020; 201:A2926.
- 56Casey S, Schelleman A, Angus P. Recurrence of hepatopulmonary syndrome post-orthotopic liver transplantation in a patient with noncirrhotic portal hypertension. Hepatology 2013; 58: 2205-2206.
- 57Swanson KL, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008; 8: 2445-2453.
- 58Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 6: 443-450.
- 59Sitbon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med 2019; 7: 594-604.
- 60Krowka M, Cottreel E, Hoeper MM, Kim NH, Martin N, Sitbon O, et al. Macitentan improves risk categorization for liver transplant mortality in patients with portopulmonary hypertension: a PORTICO study post hoc analysis. Liver Transpl 2020; 26: 935-940.
- 61Deroo R, Trepo E, Holvoet T, De Pauw M, Geerts A, Verhelst X, et al. Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis. Hepatology 2020; 72: 1701-1716.
